Eucope Visual

EUCOPE – the European Confederation of Pharmaceutical Entrepreneurs

Conferences and next Working Groups

  • 7 September 2015: EUCOPE/EMIG Legal Group Conference Call
  • 9 September 2015: EUCOPE Pharmacovigilance / Regulatory Working Group in Brussels
  • 22 September 2015: EUCOPE Pricing & Reimbursement / Market Access Working Group Meeting in Brussels
  • 14 October 2015: EUCOPE Board Meeting in Brussels
  • 9 November 2015: EUCOPE/EMIG Legal Meeting in London
  • 26 November 2015: EUCOPE Orphan Medicinal Products Working Group Meeting in Brussels

European Biotechnology – A Medical Focus

EUCOPE is proud to be part of the 2014 publication “European Biotechnology – A Medical Focus” by Horn Publishing. Alexander Natz has contributed with a foreword on the Impact of Clinical Trial Data Transparency for Biotechnology in Europe. An online version of the publication can be found here.

european_biotechnology_book_cover_stor

Market Access in Emerging Market – Unmet Needs and Growth Potential

23 September – Webinar


Eucope-LOGO-RZ_4c

 

Emerging markets are a diverse group of countries with significant unmet health needs. For the past decades, emerging markets like the BRICMT countries, second-tier countries like Southeast Asia, and Sub-Saharan Africa have been solely seen as pure marketplace for selling products. However, having the highest growth rates in terms of population and GDP, these markets offer an opportunity for companies to open up new markets for research, manufacturing as well as for existing products.

Please find more information on Webinar here.

Value Assessment & Pricing in France, the UK and Germany

24 September 2015 in Berlin

FORUM

Harmonisation of the drug value assessment in Europe still has far to go. The most promising projects to date are related to Multi-HTA early dialogues. This meeting gives you an up-to-the-minute update on the harmonisation efforts as well as on national value assessment and pricing in France, Germany and the UK.

  • What is the role of health economics in the different systems?
  • How are orphan drugs, cancer drugs and drugs for chronic diseases assessed?

After having attended this meeting you will be aware of the current status of and the challenges for the national systems in the UK, France and Germany, and have a sound perspective on what you can expect from the European HTA cooperations.

Please find more information here.

Medical Devices: Value Assessment/HTA in France, the UK and Germany

25 September in Berlin

FORUMHealth economics for Medical Devices – where are we heading in Europe? Benefit assessment in the field of medical devices is of major importance in the national healthcare systems. This meeting focuses on the current developments and challenges in three major EU countries, while also examining trends and tendencies across Europe. Please find mor information on the event held in Berlin here.

 

Welcome!

EUCOPE provides a platform for discussion for pharmaceutical entrepreneurs. On a regular basis owners and CEOs of pharmaceutical companies and associations discuss solutions to improve the quality of life for patients and to strengthen the competitiveness of the European pharmaceutical industry.

The legal framework for pharmaceutical markets is set largely by the EU institutions. An active role in the political debate on the EU level is therefore more important than ever before. The early perception of future markets and reliable regulatory circumstances are key aspects for entrepreneurial success.

Knowledge about this legal framework and the active discussion and participation on the EU level is therefore essential for pharmaceutical entrepreneurs in order to generate innovations.

EU Flag

Our services

EUCOPE understands itself as service provider for its members. The association provides its members with an early understanding about regulatory developments.

Current regulatory topics are:

A tight monitoring and comprehensive information about future market conditions are valuable assets for entrepreneurial decisions. Questions such as access to finance, market access and reliable reimbursement conditions are of crucial importance for pharmaceutical entrepreneurs.

Please find out more about EUCOPE under About us.

EUCOPE in the News

EUCOPE is in regular contact with the press on current developments in the EU and national pharma markets.

Please find some examples here.